^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

The Novel HSP90 Inhibitor, IPI-493, Is Highly Effective in Human Gastrostrointestinal Stromal Tumor Xenografts Carrying Heterogeneous KIT Mutations

Excerpt:
The combination of IPI-493 with SUN remarkably enhances antitumor effects in GIST, especially in tumors carrying double KIT mutations. 
DOI:
10.1158/1078-0432.CCR-11-0562